Paula G. O’Connor

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Roy S. Herbst, Rafat Ansari, F. Bustin et al. · The Lancet · 2011 · 391 citations · Full text

Oncology, Erlotinib Versus Erlotinib, Medicine +7

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

Fairooz F. Kabbinavar, V.A. Miller, B. E. Johnson et al. · Journal of Clinical Oncology · 2010 · 110 citations

Cancer Management, Pathology, First-line Treatment +17

Impaired CTL Recognition of Cells Latently Infected with Kaposi’s Sarcoma-Associated Herpes Virus

Christian Brander, Todd J. Suscovich, Yun Jung Lee et al. · The Journal of Immunology · 2000 · 83 citations · Full text

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

Wyndham H. Wilson, Martin Gutierrez, Paula G. O’Connor et al. · Seminars in Oncology · 2002 · 82 citations

Hematological Malignancy, Lymphoid Neoplasia, Aggressive B-cell Lymphoma +8

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

V. A. Miller, Paula G. O’Connor, C. Soh et al. · Journal of Clinical Oncology · 2009 · 67 citations

Cancer Management, First-line Treatment, Pharmacotherapy +19